Sarepta Therapeutics (SRPT)
(Real Time Quote from BATS)
$135.56 USD
+2.48 (1.86%)
Updated Aug 15, 2024 12:34 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Brokerage Reports
Sarepta Therapeutics, Inc. [SRPT]
Reports for Purchase
Showing records 581 - 600 ( 672 total )
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Confirmatory Study Dosing and NDA Submission Timelines Remain on Track
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FDA Draft Guidance on Serious Conditions Implies Advantage Eteplirsen
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Surprise CHMP Decision Establishes the Dire Clinical Need in DMD.
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We initiate SRPT with a BUY rating and a $52 price target
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1:14 Update-Eteplirsen NDA Filing Anticipated by YE:14 for Potential Accelerated Approval by H2:15
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Recent FDA DMD Guidance May Put Pressure on EMA for Ataluren?s Conditional Approval - ISIS?s SMA Updates at AAN Informative to PTCT?s Program
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Recent FDA DMD Guidance May Put Pressure on EMA for Ataluren?s Conditional Approval - ISIS?s SMA Updates at AAN Informative to PTCT?s Program
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Raising Price Target to $60 - NDA Filing YE:14 - Path Forward Suggests FDA Open to Accelerated Approval
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 14
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 7
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MDA Conference Preview: DMD and SMA Updates - RNA''s DEMAND V Data Monday
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MDA Conference Preview: DMD and SMA Updates - RNA''s DEMAND V Data Monday
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C